Safety and Efficacy of a Probiotic Supplement in IBS-D

Inclusion criteria * Males and females aged ≥18 to ≤ 65 years. * Participants diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) as per ROME IV criteria: i) Recurrent abdominal pain on average at least one day/week in the last three months, associated with two or more of the following criteria: * Related to defecation * Associated with a change in stool frequency (increase/decrease in frequency). * Associated with a change in the form (appearance) of stool. ii) History of abnormal bowel movements predominantly diarrhoea (\>25% of bowel movements categorised as stool form type 6 or 7 (diarrhoea) and \<25% as stool form type 1 or 2 (constipation) on BSFS). * Participants with an IBS-SSS score ≥ 175. * Participants who test negative for COVID-19 by Rapid Antigen Test Device. * Participants who did not change their diet within three months before the screening day and are willing to sustain that diet during the study. * Participants who can comply and perform the procedures as per the protocol (consumption of study products, biological sample collection procedures, and study visit schedule). * Participants who are literate enough to understand the purpose of the study and their rights. * Participants who are able to give written informed consent and are willing to participate in the study. Exclusion criteria * Participants who score ≥ 40 in either the 'state' or 'trait' section of the STAI-AD questionnaire (both sections to be assessed). * Participa…